In addition, patients with LC had lower antibody levels (33.26, IQR 94.18) than those in the control group (49.10, IQR 87.93; p = 0.0316), as shown in Figure 2A. Furthermore, the subgroup analysis revealed that there were no statistically significant disparities in CD19+ B-cell levels between NSCLC patients (7.59; IQR 3.43) and healthy individuals (6.61; IQR 5.25; p = 0.6859). The gene discussed is CD19; the disease is non-small cell lung carcinoma.